Ro: $5B valuation, IPO Readiness 75, Late Stage / Pre-IPO. Filed S-1 with the SEC on February 2026 — IPO actively in progress. Track live on The IPO Stack.
Direct-to-patient healthcare platform offering telemedicine, diagnostics, and pharmacy for chronic conditions.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Ro IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Ro filed its S-1 registration statement with the SEC on February 14, 2026. The IPO timeline depends on SEC review and market conditions. Track the latest signals on TechStackIPO.
Ro is valued at $5B as of the most recent funding round. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Ro shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Ro scores 75/100 (Grade: B) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Yes — Ro filed an S-1 registration statement with the SEC on February 14, 2026, indicating an active IPO process.
Ro has raised $1.1B in total venture capital and private equity funding, with backing from General Catalyst.
Ro's notable investors include General Catalyst. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Ro is a Healthcare Technology company. Direct-to-patient healthcare platform offering telemedicine, diagnostics, and pharmacy for chronic conditions.